7s59

Publication Abstract from PubMed

As natural chemokine inhibitors, evasin proteins produced in tick saliva are potential therapeutic agents for numerous inflammatory diseases. Engineering evasins to block the desired chemokines and avoid off-target side effects requires structural understanding of their target selectivity. Structures of the class A evasin EVA-P974 bound to human CC chemokine ligands 7 and 17 (CCL7 and CCL17) and to a CCL8-CCL7 chimera reveal that the specificity of class A evasins for chemokines of the CC subfamily is defined by conserved, rigid backbone-backbone interactions, whereas the preference for a subset of CC chemokines is controlled by side-chain interactions at four hotspots in flexible structural elements. Hotspot mutations alter target preference, enabling inhibition of selected chemokines. The structure of an engineered EVA-P974 bound to CCL2 reveals an underlying molecular mechanism of EVA-P974 target preference. These results provide a structure-based framework for engineering evasins as targeted antiinflammatory therapeutics.

Structure-guided engineering of tick evasins for targeting chemokines in inflammatory diseases.,Bhusal RP, Aryal P, Devkota SR, Pokhrel R, Gunzburg MJ, Foster SR, Lim HD, Payne RJ, Wilce MCJ, Stone MJ Proc Natl Acad Sci U S A. 2022 Mar 1;119(9). pii: 2122105119. doi:, 10.1073/pnas.2122105119. PMID:35217625^[2]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.